In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...
Industry, FDA Discuss Benefits of Data Sharing in Biomarker Development Data sharing is critical to the validation of new biomarkers used in drug development, experts at the seventh annual Predictive ...
Clinical Trials Arena on MSN
The slow march of clinical biomarkers to become surrogate endpoints
Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M ...
Regulators remain cautious about adopting biomarkers as surrogate endpoints for drug approvals, despite industry calls for faster integration. While the FDA and CMS have launched the RAPID pathway to ...
Key market opportunities in the CNS Biomarkers sector include utilizing AI and technologies like ML and NLP to enhance drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results